Glaxosmithkline Asia Private Limited, a active private limited company, was established on 18 October 1995 in Patiala, Punjab, India. Engaging in ayurvedic products & services within the manufacturing sector, it holds CIN: U99999PB1995PTC028476. Registered under ROC Roc Chandigarh. it is unlisted. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹5.50 Cr.
It upholds a compliant status. Employing 789 professional, Its leadership includes Ramesh Chander Gupta (Director), Anurita Chopra (Whole-Time Director), Kanika Shah Wadhwa (Whole-Time Director). Past directors included Thyagarajan Venkatraman, Krishan Kumar Khullar, Puthiyadath Narayanan Haridas. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Road Nabha India, Patiala, Punjab, 147201.
U99999PB1995PTC028476
028476
18 October 1995
₹10.00 Cr
₹5.50 Cr
Roc Chandigarh
Unlisted
Active
Explore comprehensive insights into Glaxosmithkline Asia Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramesh Chander Gupta | Director | 01 Oct 2008 | Current |
| Anurita Chopra | Whole-Time Director | 05 Sep 2016 | Current |
| Kanika Shah Wadhwa | Whole-Time Director | 12 Mar 2019 | Current |
| Nitin Mathur | Whole-Time Director | 30 Jan 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 01 Apr 2007 | Past |
| Pramod Abcsdd | Alternate Director | 01 Apr 2007 | Past |
| Pramod Abcsdd | Wholetime Director | 01 Jan 2010 | Past |
| Pramod Abcsdd | Alternate Director | 01 Apr 2007 | Past |
| Pramod Abcsdd | Alternate Director | 01 Apr 2007 | Past |
| Pramod Abcsdd | Director | 27 Sep 2012 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Glaxosmithkline Asia Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.62% increase. The company also saw a substantial fall in profitability, with a 19.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.22%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Glaxosmithkline Asia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Glaxosmithkline Asia has a workforce of 789 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Glaxosmithkline Asia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glaxosmithkline Asia's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Glaxosmithkline Asia Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Glaxosmithkline Asia Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chandigarh. was completed.
The activity Nitin Mathur was appointed as a Whole-Time Director was appointed as a Whole-Time Director on 30 Jan 2021 & has been associated with this company since 4 years 4 months . was completed.
Progress on Kanika Shah Wadhwa was appointed as a Whole-Time Director was appointed as a Whole-Time Director on 12 Mar 2019 & has been associated with this company since 6 years 3 months . was documented.
Anurita Chopra was appointed as a Whole-Time Director was appointed as a Whole-Time Director on 05 Sep 2016 & has been associated with this company since 8 years 9 months . was recorded as a recent event.
Ramesh Chander Gupta was appointed as a Director was appointed as a Director on 01 Oct 2008 & has been associated with this company since 16 years 8 months . was recorded as a recent event.
The CIN of Glaxosmithkline Asia Private Limited is U99999PB1995PTC028476.
Glaxosmithkline Asia Private Limited is headquartered at Road Nabha India, Patiala, Punjab, 147201.
Glaxosmithkline Asia Private Limited was incorporated on 18 October 1995.
The current directors of Glaxosmithkline Asia Private Limited are
The primary industry of Glaxosmithkline Asia Private Limited is Manufacturing.
Glaxosmithkline Asia Private Limited is unlisted.
The authorized capital of Glaxosmithkline Asia Private Limited is ₹10.00 Cr, and the paid-up capital is ₹5.50 Cr.
The compliance status of Glaxosmithkline Asia Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX